TY - JOUR
T1 - Perspectives on Subcutaneous Infliximab for Rheumatic Diseases and Inflammatory Bowel Disease
T2 - Before, During, and After the COVID-19 Era
AU - Schreiber, Stefan
AU - Ben-Horin, Shomron
AU - Alten, Rieke
AU - Westhovens, René
AU - Peyrin-Biroulet, Laurent
AU - Danese, Silvio
AU - Hibi, Toshifumi
AU - Takeuchi, Ken
AU - Magro, Fernando
AU - An, Yoorim
AU - Kim, Dong Hyeon
AU - Yoon, Sang Wook
AU - Reinisch, Walter
N1 - Publisher Copyright:
© 2022, The Author(s).
PY - 2022/6
Y1 - 2022/6
N2 - The coronavirus disease 2019 (COVID-19) pandemic has prompted significant changes in patient care in rheumatology and gastroenterology, with clinical guidance issued to manage ongoing therapy while minimising the risk of nosocomial infection for patients and healthcare professionals (HCPs). Subcutaneous (SC) formulations of biologics enable patients to self-administer treatments at home; however, switching between agents may be undesirable. CT-P13 SC is the first SC formulation of infliximab that received regulatory approval and may be termed a biobetter as it offers significant clinical advantages over intravenous (IV) infliximab, including improved pharmacokinetics and a convenient mode of delivery. Potential benefits in terms of reduced immunogenicity have also been suggested. With a new SC formulation, infliximab provides an additional option for dual formulation, which enables patients to transition from IV to SC administration route without changing agent. Before COVID-19, clinical trials supported the efficacy and safety of switching from IV to SC infliximab for patients with rheumatoid arthritis and inflammatory bowel disease (IBD), and SC infliximab may have been selected on the basis of patient and HCP preferences for SC agents. During the pandemic, patients with rheumatic diseases and IBD have successfully switched from IV to SC infliximab, with some clinical benefits and high levels of patient satisfaction. As patients switched to SC therapeutics, the reduction in resource requirements for IV infusion services may have been particularly welcome given the pandemic, facilitating reorganisation and redeployment in overstretched healthcare systems, alongside pharmacoeconomic benefits and a reduction in exposure to nosocomial infection. Telemedicine and contactless healthcare have been pushed to the forefront during the pandemic, and a lasting shift towards remote patient management and community/home-based drug administration is anticipated. SC infliximab supports the implementation of this paradigm for future improvements of healthcare value delivered. The accumulation of real-world data during the pandemic supports the high level of confidence, with patients, physicians, and healthcare systems benefitting from its uptake. Graphical Abstract: [Figure not available: see fulltext.]
AB - The coronavirus disease 2019 (COVID-19) pandemic has prompted significant changes in patient care in rheumatology and gastroenterology, with clinical guidance issued to manage ongoing therapy while minimising the risk of nosocomial infection for patients and healthcare professionals (HCPs). Subcutaneous (SC) formulations of biologics enable patients to self-administer treatments at home; however, switching between agents may be undesirable. CT-P13 SC is the first SC formulation of infliximab that received regulatory approval and may be termed a biobetter as it offers significant clinical advantages over intravenous (IV) infliximab, including improved pharmacokinetics and a convenient mode of delivery. Potential benefits in terms of reduced immunogenicity have also been suggested. With a new SC formulation, infliximab provides an additional option for dual formulation, which enables patients to transition from IV to SC administration route without changing agent. Before COVID-19, clinical trials supported the efficacy and safety of switching from IV to SC infliximab for patients with rheumatoid arthritis and inflammatory bowel disease (IBD), and SC infliximab may have been selected on the basis of patient and HCP preferences for SC agents. During the pandemic, patients with rheumatic diseases and IBD have successfully switched from IV to SC infliximab, with some clinical benefits and high levels of patient satisfaction. As patients switched to SC therapeutics, the reduction in resource requirements for IV infusion services may have been particularly welcome given the pandemic, facilitating reorganisation and redeployment in overstretched healthcare systems, alongside pharmacoeconomic benefits and a reduction in exposure to nosocomial infection. Telemedicine and contactless healthcare have been pushed to the forefront during the pandemic, and a lasting shift towards remote patient management and community/home-based drug administration is anticipated. SC infliximab supports the implementation of this paradigm for future improvements of healthcare value delivered. The accumulation of real-world data during the pandemic supports the high level of confidence, with patients, physicians, and healthcare systems benefitting from its uptake. Graphical Abstract: [Figure not available: see fulltext.]
KW - Biobetters
KW - CT-P13 SC
KW - Coronavirus disease 2019 (COVID-19)
KW - Inflammatory bowel disease
KW - Innovative biologics
KW - Real-world evidence
KW - Rheumatic diseases
KW - Subcutaneous infliximab
KW - Telemedicine
UR - http://www.scopus.com/inward/record.url?scp=85122363368&partnerID=8YFLogxK
U2 - 10.1007/s12325-021-01990-6
DO - 10.1007/s12325-021-01990-6
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.systematicreview???
C2 - 34988877
AN - SCOPUS:85122363368
SN - 0741-238X
VL - 39
SP - 2342
EP - 2364
JO - Advances in Therapy
JF - Advances in Therapy
IS - 6
ER -